iCo Therapeutics Inc., a Vancouver based reprofiling development company, have announced their intention to recruit patients for a Phase II DME clinical trial of their… Read More »iCo Therapeutics recruiting for Phase II DME study
A research report produced by an Australian economics consulting firm claims to be the first study to quantify the burden of visual impairment in Japan.… Read More »First study on the economic costs of visual impairment in Japan
Commentary from the UK’s Royal College of Ophthalmologists (RCO) has advised against the off-label use of Avastin (bevacizumab) for the treatment of wet age-related macular… Read More »VP of UK’s Royal College of Ophthalmologists advises against off-label use of Avastin
Clinicians and researchers from New York’s Columbia University have reported the delivery of a healthy baby girl following the first use of pre-implantation genetic diagnosis… Read More »IVF assists couple in having a child unaffected by Stargardt disease
A multi-centre Phase I/II clinical trial has presented initial results for a new topical drug focused on the treatment of diabetic eye disease. The clinical… Read More »New topical drug for DME reports results from a Phase I/II clinical trial
Recent analysis of 662 manuscripts submitted to Clinical and Experimental Ophthalmology (CEO) have identified the top 7 reasons why manuscript submissions fail to survive the… Read More »Publish or perish – insiders advice on how to avoid the rejection slip
Pooled population studies from Europe, the US, Asia and Australia have shown that approximately 16 million people are estimated to be affected by retinal vein… Read More »Global estimates show that almost 16 million people may suffer retinal vein occlusion (RVO)
Recent research from McGill University and the University of Montreal, Canada has shown that objective measures of visual function following treatment do not necessarily agree… Read More »Mind the gap – satisfaction with treatment differs between patients and doctors
xxxxx
A gene therapy treatment of 12 patients between the ages of 8-44 years suffering RPE65-associated Leber’s Congenital Amaurosis (LCA) has been shown to improve vision… Read More »Phase 1 dose escalation study on gene therapy treatment for LCA shows importance of early treatment